Autopsy report · NCT03099161
Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)
Cause of deathFutility
“The data did not support study endpoints”
Life of this trial
- Registered 3 months before it started.
- Ran for about 8 months before it stopped.
- 10 participants enrolled.
- Results were posted on the registry 1 year 3 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Conditions
- Neoplasm
- Interventions
- preladenant; pembrolizumab
- Participants
- 10
- Sites
- 5
- Countries
- Canada, Israel, United States
Trials that died the same way
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
“The study did not meet endpoint.” - A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
“The study did not meet the primary endpoint.” - Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS)
“The study was terminated as its Part A did not meet the primary endpoint.” - Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
“Study design was inadequate and would not achieve study endpoints” - Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
“No results are avaialble as the study did not complete according to the protocol”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.